Anti-mitotic potential of 7-diethylamino-3(2'-benzoxazolyl)-coumarin in 5-fluorouracil-resistant human gastric cancer cell line SNU620/5-FU

Biochemical and Biophysical Research Communications

Volumn 418, Issue 4, 2012, Pages 616-621

  Kim, Nam Hyun ^a   Kim, Su Nam ^b   Oh, Joa Sub ^c   Lee, Seokjoon ^a   Kim, Yong Kee ^d  

^a Catholic Kwandong University   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c Dankook University   (South Korea)

^d Sookmyung Women's University   (South Korea)

Author keywords

5FU; 7 Diethylamino 3(2' benzoxazolyl) coumarin; Drug resistance; Microtubule

Indexed keywords

7 DIETHYLAMINO 3 (2' BENZOXAZOLYL)COUMARIN; ANTINEOPLASTIC AGENT; COUMARIN DERIVATIVE; FLUOROURACIL; PACLITAXEL; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DEPHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; MICROTUBULE; MITOSIS; MOUTH CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SQUAMOUS CELL CARCINOMA; STOMACH CANCER;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTIMITOTIC AGENTS; APOPTOSIS; BENZOXAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; COUMARINS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; STOMACH NEOPLASMS; TUBULIN MODULATORS;

EID: 84862793621     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.01.049     Document Type: Article

References (21)

1. Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4:253-265.
2. Nogales E. Structural insights into microtubule function. Annu. Rev. Biochem. 2000, 69:277-302.
3. de Forges H., Bouissou A., Perez F. Interplay between microtubule dynamics and intracellular organization. Int. J. Biochem. Cell Biol. 2011.
4. Jordan M.A., Kamath K. How do microtubule-targeted drugs work? An overview. Curr. Cancer Drug Targets 2007, 7:730-742.
5. Checchi P.M., Nettles J.H., Zhou J., Snyder J.P., Joshi H.C. Microtubule-interacting drugs for cancer treatment. Trends Pharmacol. Sci. 2003, 24:361-365.
6. Jackson J.R., Patrick D.R., Dar M.M., Huang P.S. Targeted anti-mitotic therapies: can we improve on tubulin agents?. Nat. Rev. Cancer 2007, 7:107-117.
7. Pellegrini F., Budman D.R. Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest. 2005, 23:264-273.
8. Pasquier E., Kavallaris M. Microtubules: a dynamic target in cancer therapy. IUBMB Life 2008, 60:165-170.
9. Lee J.J., Swain S.M. Peripheral neuropathy induced by microtubule-stabilizing agents. J. Clin. Oncol. 2006, 24:1633-1642.
10. Kavallaris M., Annereau J.P., Barret J.M. Potential mechanisms of resistance to microtubule inhibitors. Semin. Oncol. 2008, 35:S22-27.
11. Lee S., Sivakumar K., Shin W.S., Xie F., Wang Q. Synthesis and anti-angiogenesis activity of coumarin derivatives. Bioorg. Med. Chem. Lett. 2006, 16:4596-4599.
12. Kim S.N., Kim N.H., Park Y.S., Kim H., Lee S., Wang Q., Kim Y.K. 7-Diethylamino-3(2'-benzoxazolyl)-coumarin is a novel microtubule inhibitor with antimitotic activity in multidrug resistant cancer cells. Biochem. Pharmacol. 2009, 77:1773-1779.
13. Kang H.C., Kim I.J., Park J.H., Shin Y., Ku J.L., Jung M.S., Yoo B.C., Kim H.K., Park J.G. Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin. Cancer Res. 2004, 10:272-284.
14. Park J.G., Yang H.K., Kim W.H., Chung J.K., Kang M.S., Lee J.H., Oh J.H., Park H.S., Yeo K.S., Kang S.H., Song S.Y., Kang Y.K., Bang Y.J., Kim Y.H., Kim J.P. Establishment and characterization of human gastric carcinoma cell lines. Int. J. Cancer 1997, 70:443-449.
15. King K.L., Cidlowski J.A. Cell cycle and apoptosis: common pathways to life and death. J. Cell Biochem. 1995, 58:175-180.
16. Norbury C., Nurse P. Animal cell cycles and their control. Annu. Rev. Biochem. 1992, 61:441-470.
17. Bassermann F., Peschel C., Duyster J. Mitotic entry: a matter of oscillating destruction. Cell Cycle 2005, 4:1515-1517.
18. Marumoto T., Zhang D., Saya H. Aurora-A - a guardian of poles. Nat. Rev. Cancer 2005, 5:42-50.
19. Carvajal R.D., Tse A., Schwartz G.K. Aurora kinases: new targets for cancer therapy. Clin. Cancer Res. 2006, 12:6869-6875.
20. Keen N., Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer 2004, 4:927-936.
21. Crosio C., Fimia G.M., Loury R., Kimura M., Okano Y., Zhou H., Sen S., Allis C.D., Sassone-Corsi P. Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol. Cell Biol. 2002, 22:874-885.